For clinical trials more specific IKK1-inhibitors are needed such as those now being explored to treat cancer [44, 45] and it has also to be proven first experimentally that treatment with a specific IKK1-inhibitor also reduces injury in the IRI-model even when given with some delay after the disease was established. Here, CHUK is linked to cancer.